Skip to content
2000
Volume 3, Issue 1
  • ISSN: 2212-697X
  • E-ISSN: 2212-6988

Abstract

Background: Prostate cancer (PCa) patients shall develop eventually incurable bone metastasis. Although advanced prostate cancer is the best known example of androgen- dependent neoplasia, PCa patients after an excellent clinical response to adrogen ablation therapies (medical or surgical castration) will ultimately become castration resistant (CRPC). Methods: Analysis of cell-cell interactions within the sites of osteoblastic metastasis has revealed that survival factors (inhibitors of chemotherapy-induced apoptosis and androgen deprivation/medical or surgical castration-induced apopptosis) for prostate cancer cells are activated, locally. Results: The analysis of these cell-cell interactions between metastatic PCa cells and host tissue (bone) revealed that insulin-like growth factor I, transforming growth factor beta 1 (TGFβ1), interleukin 6 (IL-6) are the most important survival factors for prostate cancer cells residing in bones. Suppression of the bioavailability of such survival factors which can achieved by the administration of dexamethasone plus somatostatin analogues (anti-survival factor therapy: ASF therapy) was proven an effective hormonal manipulation for the treatment of CRPC. Conclusion: The present review provides an update on bone microenvironment cell-cell interactions forming the concept of the ASF therapy for CRPC.

Loading

Article metrics loading...

/content/journals/ccand/10.2174/2212697X03666151203202934
2016-05-01
2025-06-01
Loading full text...

Full text loading...

/content/journals/ccand/10.2174/2212697X03666151203202934
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test